"The voice for cancer physicians and their patients in Massachusetts."
The U.S. Food and Drug Administration approved atezolizumab (Tecentriq, Genentech, Inc.) in combination with cobimetinib and vemurafenib for patients with BRAF V600 mutation-positive unresectable or metastatic melanoma. Read full press release.
Massachusetts Society of Clinical Oncologists (c) 860 Winter Street, Waltham, MA. 02451
Waltham, MA. 02451